Tumor Profiling

Tumor Profiling Market Outlook

The global tumor profiling market is expected to reach approximately USD 10.2 billion by 2035, growing at a compound annual growth rate (CAGR) of 12.5% during the forecast period of 2025 to 2035. The rising prevalence of cancer across various demographics and the increasing demand for personalized medicine are considered significant factors driving the growth of this market. Furthermore, advancements in technology that allow for more efficient and accurate tumor profiling tests are contributing to a broader acceptance of these diagnostic tools in clinical settings. Additionally, the growing emphasis on early cancer detection and the rising investment in cancer research and development initiatives further stimulate market growth. Enhanced awareness and education regarding cancer and its various treatment modalities also play a vital role in expanding the market landscape.

Growth Factor of the Market

One of the primary growth factors contributing to the tumor profiling market is the increasing incidence of cancer globally, which necessitates effective diagnostic and therapeutic strategies. As cancer types become more diverse and complex, there is a rising emphasis on personalized treatment plans that are tailored to individual genetic profiles. This trend has led to a surge in the utilization of tumor profiling technologies, as they offer insights into the specifics of tumor characteristics, enabling healthcare providers to devise targeted therapies. Moreover, technological advancements in genomic sequencing and biomarker identification have made tumor profiling increasingly accessible and affordable, further propelling market growth. Additionally, the integration of tumor profiling in routine clinical practice allows for improved patient outcomes and optimized resource utilization within healthcare systems. The rising healthcare expenditure and investment in biotechnology research also foster innovations in tumor profiling technologies.

Key Highlights of the Market

• Significant growth anticipated in the tumor profiling market driven by the rising cancer prevalence and demand for personalized medicine.
• Technological advancements in genomic sequencing are improving the accuracy and efficiency of tumor profiling.
• Increasing healthcare expenditure is facilitating innovations in cancer diagnostics and biomarker discovery.
• The growing adoption of next-generation sequencing technologies is reshaping the tumor profiling landscape.
• Collaboration between research institutes and healthcare providers is enhancing the development of innovative profiling solutions.

By Technology

Next-Generation Sequencing:

Next-Generation Sequencing (NGS) stands at the forefront of tumor profiling technologies due to its unparalleled ability to analyze large amounts of genetic data quickly and with high precision. NGS facilitates the comprehensive characterization of tumor genomes, offering insights into mutations, copy number variations, and other genetic alterations that may be pivotal in determining treatment pathways. The technology’s scalability and cost-effectiveness have led to its widespread adoption in both clinical and research settings, making it a preferred choice for oncologists seeking to personalize treatment plans for their patients. With continued advancements in sequencing methods, the accuracy and depth of coverage are expected to improve further, driving the momentum for NGS in the tumor profiling market.

Polymerase Chain Reaction:

Polymerase Chain Reaction (PCR) represents a cornerstone technology in tumor profiling, particularly for the detection and quantification of specific genetic mutations and biomarkers. PCR's high sensitivity and specificity make it an essential tool for early cancer detection and monitoring therapeutic responses to treatment. The technique is widely used in laboratories due to its relatively low cost and ease of use, allowing for rapid results and real-time data monitoring. Additionally, advancements such as quantitative PCR and reverse transcriptase PCR have broadened its application scope, particularly in analyzing gene expression profiles in tumors. The demand for PCR-based tests continues to rise, driven by the need for accurate and timely diagnostics in oncology.

Immunohistochemistry:

Immunohistochemistry (IHC) is a vital technique in tumor profiling that employs antibodies to detect specific antigens in tissue samples, providing critical information about tumor type and progression. This technology is particularly useful in identifying biomarkers that guide treatment decisions and stratify patients for specific therapies. IHC's role in the classification of tumors, including the assessment of hormone receptor status in breast cancer, has solidified its place in routine clinical practice. Furthermore, continuous developments in antibody technologies and detection methods are enhancing the accuracy and reliability of IHC tests, thereby driving their adoption in both diagnostic and research applications.

In Situ Hybridization:

In Situ Hybridization (ISH) is an innovative technique that allows for the visualization of specific nucleic acid sequences within preserved tissue sections. This technology is instrumental in identifying genetic alterations associated with various cancers, providing valuable insights into tumor biology and behavior. ISH's ability to provide spatial localization of gene expression adds a layer of complexity to tumor profiling, enabling researchers and clinicians to analyze the relationships between genetic changes and tumor microenvironments. The growing interest in understanding tumor heterogeneity and its implications on treatment response is likely to boost the adoption of ISH in the coming years.

Microarray:

Microarray technology permits the simultaneous analysis of thousands of genes, enabling comprehensive profiling of tumors at the genomic level. By providing information on gene expression patterns, microarrays help in identifying potential biomarkers for diagnosis, prognosis, and treatment response. The ability to dissect the molecular underpinnings of tumors is invaluable in discovering new therapeutic targets, which is crucial for personalized medicine. As researchers increasingly focus on understanding the complexities of cancer at a molecular level, the demand for microarray technologies is expected to rise, driving their integration into tumor profiling workflows.

By Cancer Type

Breast Cancer:

Breast cancer remains one of the most common malignancies globally, leading to a heightened focus on tumor profiling to improve diagnosis and treatment strategies. Profiling in breast cancer allows for the identification of specific biomarkers like HER2 and estrogen receptors, which are critical in guiding treatment decisions. The integration of tumor profiling in breast cancer management has led to the development of targeted therapies that have significantly improved patient outcomes. Furthermore, ongoing research into the genetic and molecular factors contributing to breast cancer subtypes continues to enhance the understanding of this disease, driving the demand for sophisticated profiling technologies.

Lung Cancer:

Lung cancer is another prevalent cancer type where tumor profiling plays a critical role in determining effective treatment strategies. With the identification of key mutations such as EGFR, ALK, and KRAS, tumor profiling has revolutionized the management of non-small cell lung cancer (NSCLC). The ability to tailor therapies based on the molecular characteristics of a patient's tumor has resulted in improved survival rates and quality of life. The advancement of liquid biopsy technologies is further enhancing the potential of tumor profiling in lung cancer, enabling less invasive sampling methods and real-time monitoring of treatment responses.

Colorectal Cancer:

Colorectal cancer is among the leading causes of cancer-related deaths, emphasizing the need for effective profiling tools to aid in early detection and personalized treatment. Tumor profiling in colorectal cancer enables the identification of specific genetic markers that can influence the choice of therapy, including targeted treatments and immunotherapy. Additionally, profiling can help assess the risk of recurrence and monitor treatment efficacy, making it an essential component of comprehensive cancer care. The growing awareness of the genetic basis of colorectal cancer is likely to increase the demand for profiling technologies in this segment.

Prostate Cancer:

Prostate cancer is a significant health concern for men worldwide, and tumor profiling is crucial for guiding treatment decisions in this heterogeneous disease. The identification of biomarkers such as PSA (Prostate-Specific Antigen) and genetic alterations like BRCA mutations has transformed the approach to diagnosing and treating prostate cancer. Profiling allows for risk stratification, enabling healthcare providers to tailor treatment options based on the aggressiveness of the cancer. As research in prostate cancer biology advances, the role of tumor profiling in enhancing patient management and therapy selection is expected to grow.

Others:

In addition to the aforementioned cancer types, tumor profiling is increasingly being applied to a variety of other cancers, including pancreatic, ovarian, and head and neck cancers. Each of these cancer types presents unique challenges, and profiling technologies are essential for uncovering the molecular mechanisms underlying their development and progression. The ongoing research efforts aimed at identifying novel biomarkers and therapeutic targets specific to these cancers will drive the adoption of tumor profiling technologies. By expanding the scope of tumor profiling to encompass additional cancer types, the market is poised for significant growth in the coming years.

By Biomarker Type

Genomic Biomarkers:

Genomic biomarkers represent a critical aspect of tumor profiling, providing insights into the genetic alterations present in tumors. These biomarkers can indicate susceptibility to certain cancer types, predict treatment responses, and help monitor disease progression. With advancements in sequencing technologies, the identification and validation of genomic biomarkers have accelerated, allowing for more personalized therapeutic approaches. The integration of genomic profiling in clinical practice has become a standard procedure for many cancers, affirming its importance in the overall landscape of tumor profiling.

Proteomic Biomarkers:

Proteomic biomarkers focus on the study of proteins expressed by tumors, offering complementary information to genomic profiling. By analyzing protein expression patterns, proteomics can reveal crucial insights into tumor behavior, treatment resistance, and potential therapeutic targets. The ability to detect and quantify specific proteins provides significant advantages in understanding tumor microenvironments and the biological mechanisms driving cancer progression. The growing emphasis on proteomics in research and clinical settings is fostering the development of novel diagnostic and treatment strategies.

Epigenetic Biomarkers:

Epigenetic biomarkers have gained prominence in tumor profiling as they provide valuable insights into the regulatory mechanisms underlying gene expression in tumors. Changes in DNA methylation and histone modifications can significantly impact tumor development and response to therapies. The identification and monitoring of epigenetic alterations are becoming increasingly important for understanding cancer biology and patient stratification. As research continues to unveil the complexities of epigenetics in cancer, the inclusion of epigenetic biomarkers in tumor profiling is expected to expand, enriching our understanding of tumor dynamics and treatment responses.

Metabolomic Biomarkers:

Metabolomic biomarkers focus on the analysis of metabolic profiles associated with tumors, providing a unique perspective on cancer biology. The metabolic pathways altered in cancer cells often reflect their aggressiveness and response to therapies. Profiling metabolites can lead to the identification of novel biomarkers for early detection, prognosis, and treatment monitoring. As metabolomics continues to evolve, its integration into tumor profiling will play a crucial role in enhancing personalized medicine strategies, offering new avenues for targeted treatments.

Others:

Apart from genomic, proteomic, epigenetic, and metabolomic biomarkers, other emerging biomarker types are also being explored in tumor profiling. These include circulating tumor DNA (ctDNA) and exosomal biomarkers, which offer non-invasive sampling methods for monitoring tumor dynamics. The development of liquid biopsies that analyze various biomarker types is revolutionizing the field of cancer diagnostics and treatment monitoring. As the understanding of these novel biomarkers expands, their integration into tumor profiling practices will likely enhance the overall effectiveness of cancer management.

By User

Hospitals:

Hospitals serve as primary users of tumor profiling technologies, as they are often the frontline institutions for cancer diagnosis and treatment. The integration of tumor profiling into hospital protocols has significantly improved patient management through personalized therapy decisions, resulting in better patient outcomes. Hospitals are increasingly adopting advanced profiling technologies to enhance their diagnostic capabilities, streamline treatment planning, and facilitate clinical trials for new therapies. Additionally, the growing collaboration between hospitals and biotechnology companies is further driving innovation in tumor profiling solutions.

Diagnostic Laboratories:

Diagnostic laboratories are essential players in the tumor profiling market, providing specialized services for analyzing tumor samples. These labs utilize advanced technologies such as NGS and PCR to offer comprehensive profiling services that aid in cancer diagnosis and treatment monitoring. The increasing demand for precise and timely diagnostic results is pushing laboratories to invest in cutting-edge technologies and develop robust testing protocols. As the emphasis on early detection and personalized medicine grows, diagnostic laboratories play a crucial role in delivering high-quality tumor profiling data to healthcare providers.

Research Institutes:

Research institutes are at the forefront of developing and validating new tumor profiling technologies and biomarkers. These institutions engage in extensive research efforts to understand the molecular mechanisms underlying cancer and to discover novel diagnostic and therapeutic targets. The collaboration between research institutes and clinical settings is fostering the translation of laboratory findings into practical applications in patient care. As funding for cancer research expands, the contributions of research institutes to the tumor profiling market will continue to grow, driving innovation and enhancing treatment strategies.

Others:

Other users of tumor profiling technologies include pharmaceutical companies and biotechnology firms that leverage profiling data for drug development and clinical trials. These organizations utilize tumor profiling to identify patient populations for targeted therapies and to monitor treatment efficacy. The integration of tumor profiling into drug development processes is essential for advancing personalized medicine and optimizing clinical outcomes. As the landscape of cancer treatment evolves, the involvement of diverse stakeholders in the tumor profiling market is expected to expand, creating new opportunities for growth.

By Region

The tumor profiling market is geographically diverse, with North America leading in terms of market share and technological advancement. The region's robust healthcare infrastructure, high expenditure on cancer research, and a growing emphasis on personalized medicine contribute to its dominance. In 2025, the North American tumor profiling market is projected to account for approximately 40% of the global market, with an expected CAGR of 13.5% through 2035. The presence of numerous key players, along with significant investments in R&D, further solidifies North America's position as a leader in the tumor profiling landscape.

Europe is also a significant market for tumor profiling, with a strong focus on innovative diagnostic solutions and personalized treatments. The European tumor profiling market is anticipated to reach around 30% of the global market share by 2035. The growing collaboration between research institutions, healthcare providers, and biotechnology firms across Europe is enhancing the development and adoption of tumor profiling technologies. Additionally, increased government initiatives and funding aimed at cancer research are expected to drive market growth in this region, making it a vital area for future developments in tumor profiling.

Opportunities

The tumor profiling market is poised to benefit from a multitude of opportunities driven by advancements in technology and increasing awareness regarding personalized medicine. One of the most promising opportunities lies in the development of liquid biopsy techniques, which allow for non-invasive sampling of tumors through blood tests. This innovation not only enhances patient comfort but also facilitates real-time monitoring of treatment responses, making it an attractive option for both healthcare providers and patients. The potential for liquid biopsies to detect minimal residual disease and monitor for recurrence offers significant promise for improving cancer management strategies. Furthermore, the integration of artificial intelligence and machine learning algorithms into tumor profiling processes is anticipated to enhance data analysis, improve diagnostic accuracy, and pave the way for more tailored treatment approaches.

Another major opportunity for the tumor profiling market is the expanding pipeline of targeted therapies and immunotherapies that rely on precise biomarker identification. As the understanding of tumor biology evolves, the demand for comprehensive profiling that can guide treatment decisions is expected to surge. Additionally, partnerships between biotechnology companies, pharmaceutical firms, and academic institutions are fostering innovation and facilitating the development of novel profiling technologies and companion diagnostics. The growing trend towards collaborative research efforts and shared resources will ultimately enhance the capabilities of tumor profiling and lead to improved clinical outcomes for cancer patients.

Threats

Despite the promising outlook for the tumor profiling market, several threats could impede its growth trajectory. One significant threat is the increasing regulatory scrutiny and the complexities associated with obtaining approval for new diagnostic tests and technologies. The stringent regulations set forth by health authorities can lead to longer development timelines and increased costs for companies seeking to introduce innovative profiling solutions. Additionally, the need for extensive validation of biomarkers and diagnostic tests may pose challenges in effectively bringing new products to market. This regulatory burden, coupled with the competitive nature of the healthcare landscape, can deter investment and slow down innovation in the tumor profiling sector.

Another potential threat comes from the rapid advancements in technology, particularly in areas such as point-of-care testing and home diagnostics. As these technologies evolve, they may shift the focus away from traditional tumor profiling methods conducted in specialized laboratories. The emergence of alternative diagnostic approaches also raises concerns about the standardization and reliability of tumor profiling results. Companies that fail to adapt to these changes and innovate in response to shifting market demands may find themselves at a disadvantage, impacting their market share and long-term sustainability.

Competitor Outlook

• Thermo Fisher Scientific
• Illumina, Inc.
• Agilent Technologies
• Roche Diagnostics
• Myriad Genetics, Inc.
• QIAGEN N.V.
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Asuragen, Inc.
• Strata Oncology
• Foundation Medicine, Inc.
• Guardant Health, Inc.
• Invitae Corporation
• PathAI
• Neogenomics Laboratories, Inc.

The competitive landscape of the tumor profiling market is characterized by a diverse range of players, including established multinational corporations, specialized biotech firms, and research institutions. These competitors are actively engaged in developing and commercializing innovative tumor profiling technologies and tests, aiming to address the growing demand for personalized cancer diagnostics and therapies. The market is witnessing a surge in partnerships, collaborations, and mergers and acquisitions, as companies seek to enhance their capabilities and expand their market presence. Key players are increasingly focusing on investing in R&D to advance their product portfolios, optimize testing methodologies, and improve the accuracy and reliability of tumor profiling results.

Among the major companies in the tumor profiling market is Thermo Fisher Scientific, a leader in providing comprehensive solutions for genomic and proteomic analysis. Their extensive product offerings, including NGS platforms and reagents, cater to a wide range of applications in cancer research and diagnostics. Similarly, Illumina, Inc. is recognized for its pioneering advancements in sequencing technologies, providing critical tools for tumor profiling and personalized medicine. Their commitment to innovation has positioned them as a significant player in the market, facilitating collaborations with leading research institutions and healthcare organizations to drive the development of next-generation profiling solutions.

Another prominent competitor, Roche Diagnostics, has made significant strides in tumor profiling through its focus on developing targeted therapies and companion diagnostics. Their portfolio of assays and diagnostic tests aims to provide healthcare professionals with the necessary insights to make informed treatment decisions. Additionally, Myriad Genetics has established itself as a leader in hereditary cancer testing and tumor profiling, offering advanced profiling solutions that assist in identifying patients at risk and informing treatment strategies. As these companies and others continue to innovate and adapt to the evolving landscape of cancer diagnostics, the tumor profiling market is expected to experience substantial growth and transformation.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 PathAI
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 QIAGEN N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Asuragen, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Strata Oncology
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Invitae Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Agilent Technologies
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Guardant Health, Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Myriad Genetics, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 F. Hoffmann-La Roche AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Foundation Medicine, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Bio-Rad Laboratories, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Neogenomics Laboratories, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Tumor Profiling Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Laboratories
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 Tumor Profiling Market, By Technology
    • 6.2.1 Next-Generation Sequencing
    • 6.2.2 Polymerase Chain Reaction
    • 6.2.3 Immunohistochemistry
    • 6.2.4 In Situ Hybridization
    • 6.2.5 Microarray
  • 6.3 Tumor Profiling Market, By Cancer Type
    • 6.3.1 Breast Cancer
    • 6.3.2 Lung Cancer
    • 6.3.3 Colorectal Cancer
    • 6.3.4 Prostate Cancer
    • 6.3.5 Others
  • 6.4 Tumor Profiling Market, By Biomarker Type
    • 6.4.1 Genomic Biomarkers
    • 6.4.2 Proteomic Biomarkers
    • 6.4.3 Epigenetic Biomarkers
    • 6.4.4 Metabolomic Biomarkers
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Tumor Profiling Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Tumor Profiling market is categorized based on

By Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Immunohistochemistry
• In Situ Hybridization
• Microarray

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Others

By Biomarker Type

• Genomic Biomarkers
• Proteomic Biomarkers
• Epigenetic Biomarkers
• Metabolomic Biomarkers
• Others

By User

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific
• Illumina, Inc.
• Agilent Technologies
• Roche Diagnostics
• Myriad Genetics, Inc.
• QIAGEN N.V.
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc.
• Asuragen, Inc.
• Strata Oncology
• Foundation Medicine, Inc.
• Guardant Health, Inc.
• Invitae Corporation
• PathAI
• Neogenomics Laboratories, Inc.